100 years of serving patients: our Gödöllő plant, near Budapest celebrates a century of history
Sixteen years ago, we took over the legacy of a pioneering vaccines and blood derivatives company in Hungary
Kedrion announces RYPLAZIM® now available in US
Distribution resumes of medicine to treat Congenital Plasminogen Deficiency
The President and CEO of PPTA visits the Bolognana plant
The meeting was a valuable opportunity for Kedrion and PPTA to strengthen our ongoing partnership
Kedrion reinforces its commitment against Rabies
Agreement with Kamada to continue to serve patients exposed to the Rabies virus in the US and add potential territories
KEDPLASMA announces nationwide facility remodeling project
The initiative aims at enhancing the experience of its donors who stand at the beginning of a bridge between patients and their care
Kedrion attended the 75th Annual Bleeding Disorders Conference in the US
The company supported the Plasminogen Deficiency Foundation in a round-table for patients with Congenital Plasminogen Deficiency
Kedrion supports the IDF Research Grant Program for the second year
The Program encourages and supports patient-oriented research on Primary Immunodeficiencies
Kedrion confirms its commitment against Rabies infections in the US
Distribution agreement with Kamada for KEDRAB® extended until March 2026
Kedrion’s global portfolio expands to China
BPL’s Human Albumin is our first ever product approved in the Chinese market
